CliffBio
small molecule

BORTEZOMIB

BORTEZOMIB

Loss of exclusivityNovember 2032latest FDA-listed patent expiry
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameBORTEZOMIB
Active ingredientBORTEZOMIB
Strength3.5MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
8962572November 2032product

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.